New FDA Warning Added to Popular Weight Loss Drugs
Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are liraglutide (Saxenda, Victoza), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound).
A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup
Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, continued to soar in the third quarter,
Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...
16don MSN
The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...
Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with ...
Lexaria Bioscience (LEXX) has received partial 12-week body weight results from the recently completed animal study WEIGHT-A24-1. Lexaria is ...
CVS Caremark and Express Scripts, along with GoodRx and others, are accused of working together to suppress reimbursements to independent pharmacies in at least three class-action lawsuits. Also, Hims ...
Ozempic (semaglutide) and Victoza (liraglutide) are prescription drugs used to treat type 2 diabetes and reduce the risk of cardiovascular problems. Both drugs come as an injection. Ozempic and ...
Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback